458 related articles for article (PubMed ID: 18159823)
21. HPV-vaccination against cervical carcinoma: will it really work?
Gross G
Med Microbiol Immunol; 2007 Sep; 196(3):121-5. PubMed ID: 17318575
[TBL] [Abstract][Full Text] [Related]
22. The current and future role of screening in the era of HPV vaccination.
Myers E; Huh WK; Wright JD; Smith JS
Gynecol Oncol; 2008 May; 109(2 Suppl):S31-9. PubMed ID: 18482556
[TBL] [Abstract][Full Text] [Related]
23. Eurogin 2010 roadmap on cervical cancer prevention.
Franceschi S; Denny L; Irwin KL; Jeronimo J; Lopalco PL; Monsonego J; Peto J; Ronco G; Sasieni P; Wheeler CM
Int J Cancer; 2011 Jun; 128(12):2765-74. PubMed ID: 21207409
[TBL] [Abstract][Full Text] [Related]
24. Prevalence and distribution of human papillomavirus genotype in south eastern Italy, in the period 2006-2011: implications for intervention.
Guido M; Tinelli A; De Donno A; Bruno AR; Tagliaferro L; Fedele A; Carbone A; Menegazzi P; Aprile V; Greco M; Malvasi A; Piccinni MA; Turano S; Grima P; Dell' Ederam D; Zizza A
Curr Pharm Des; 2013; 19(8):1498-507. PubMed ID: 23016783
[TBL] [Abstract][Full Text] [Related]
25. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
26. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
Stanley M
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
[TBL] [Abstract][Full Text] [Related]
27. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
Du J; Ährlund-Richter A; Näsman A; Dalianis T
Arch Gynecol Obstet; 2021 Feb; 303(2):329-335. PubMed ID: 33247317
[TBL] [Abstract][Full Text] [Related]
28. HPV vaccine: a cornerstone of female health.
Temte JL
Am Fam Physician; 2007 Jan; 75(1):28, 30. PubMed ID: 17225700
[No Abstract] [Full Text] [Related]
29. HPV vaccination and the prevention of cervical cancer: the long road ahead.
Markman M
J Womens Health (Larchmt); 2007 Nov; 16(9):1366-7. PubMed ID: 18001194
[No Abstract] [Full Text] [Related]
30. Reducing the burden of cervical cancer and HPV-related diseases through vaccination. Introduction.
Cox JT
Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s3-4. PubMed ID: 16520682
[No Abstract] [Full Text] [Related]
31. Cervical cancer prevention in the human papilloma virus vaccine era.
Ghazal-Aswad S
Ann N Y Acad Sci; 2008 Sep; 1138():253-6. PubMed ID: 18837904
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus vaccine: widening the scope for cancer prevention.
No JH; Kim MK; Jeon YT; Kim YB; Song YS
Mol Carcinog; 2011 Apr; 50(4):244-53. PubMed ID: 21465574
[TBL] [Abstract][Full Text] [Related]
33. Risk of cervical cancer after HPV vaccination.
Markman M
Curr Pharm Des; 2013; 19(8):1488-9. PubMed ID: 23016781
[TBL] [Abstract][Full Text] [Related]
34. For debate: that Australia should continue using the quadrivalent vaccine.
Wain G
Sex Health; 2010 Sep; 7(3):235-7. PubMed ID: 21058496
[No Abstract] [Full Text] [Related]
35. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
36. The new era of cervical cancer prevention: HPV vaccination.
Monk BJ; Herzog TJ
Gynecol Oncol; 2008 May; 109(2 Suppl):S1-3. PubMed ID: 18482553
[No Abstract] [Full Text] [Related]
37. Human papillomavirus and vaccination in cervical cancer.
Wang KL
Taiwan J Obstet Gynecol; 2007 Dec; 46(4):352-62. PubMed ID: 18182340
[TBL] [Abstract][Full Text] [Related]
38. Harnessing the power of prevention: human papillomavirus vaccines.
Mayeaux EJ
Curr Opin Obstet Gynecol; 2006 Feb; 18 Suppl 1():s15-21. PubMed ID: 16520680
[TBL] [Abstract][Full Text] [Related]
39. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.
Brown DR; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Tay EH; Garcia P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Joura EA; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Sings HL; James M; Hesley TM; Barr E
J Infect Dis; 2009 Apr; 199(7):926-35. PubMed ID: 19236279
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
